On Wednesday, Following Stocks were among the “Top Priority Stocks” For Traders - Progenics Pharmaceuticals, (NASDAQ:PGNX), ACADIA Pharmaceuticals (NASDAQ:ACAD), Prothena (NASDAQ:PRTA), Applied Micro Circuits (NASDAQ:AMCC)
Formerly On March 16, 2015 Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) promulgated its results of operations for the fourth quarter and year-end 2014. Net loss for the quarter was $12.2 million or $0.18 diluted per share, compared to net loss of $8.6 million or $0.14 diluted per share in the 2013 period. Net income for the year-end 2014 was $4.4 million or $0.06 diluted per share, compared to net loss of $42.6 million or $0.76 diluted for each share in 2013.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)’s shares picked down -5.53%, and closed at $5.64. The stock volatility for the week is 7.26%, while for the month remained 6.86%. The company holds consensus target price of $8.67.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 0.01 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 107.90% and Annual EPS growth for the past 5 years is considered as 15.60%.
The mean recommendation of analysts for this stock is 2.30. (Where 1=Buy, 5=Sale).
Progenics Pharmaceuticals, Inc. (PGNX) develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) declined -7.28%, and closed at $31.20. The company has the market capitalization of $3.35 billion. The beta value of the stock is 2.98. On the other hand the stock’s volatility for the week is 3.89%, and for the month is 5.13%. The stock’s price to book ratio is $10.58, however price to sale ratio is $33707.21. Analyst’s mean recommendation regarding this stock is 1.80. (Where 1=Buy, 5=Sale).
ACADIA Pharmaceuticals Inc. (ACAD) a biopharmaceutical corporation focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
On March 19, 2015Prothena Corporation PLC (NASDAQ:PRTA) a late-stage clinical biotechnology corporation focused on the discovery, development and commercialization of novel protein immunotherapy programs, declared positive results from a Phase 1 single ascending dose study of PRX002, a monoclonal antibody for the potential treatment of Parkinson’s disease and other related synucleinopathies. PRX002 is the focus of a worldwide partnership between Prothena and Roche.
Prothena Corporation PLC (NASDAQ:PRTA) decreased -6.38%, and closed at $36.83. The company holds the market capitalization of $1.06 billion. For the last twelve months, the stock was able to keep return on equity at -2.60%, while return on assets at -2.50%, in response to its return on investment at -2.60%. Its 20-day moving average gained 26.48%, below 50-day moving average of 46.91%, below 200-day moving average of 66.17% from the latest market price of $36.83. The mean recommendation of analysts for this stock is 1.70. (Where 1=Buy, 5=Sale).
Prothena Corporation PLC (PRTA) a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion.
On March 23, 2015 Applied Micro Circuits Corporation (NASDAQ:AMCC) and TE Connectivity (TEL) proclaimed their collaboration to develop high-speed cable connectivity solutions for data center networks. The collaboration will result in active copper cables for connecting servers to top-of-rack (TOR) switches at 50Gbps and 40Gbps speeds using AppliedMicro’s DSP-based transceiver and TE Connectivity’s high-speed copper cable assemblies.
Applied Micro Circuits Corporation (NASDAQ:AMCC) fell -7.00%, and closed at $5.0. The stock has the beta value of 1.49, and its volatility for the week is 3.35%, while for the month it is 3.98%. The company has the market capitalization of $413.75 million. The company holds the book value per share of 1.63, whereas cash per share is 1.05. Price to book ratio remained 3.33, while price to sale ratio is 2.39. Analysts mean recommendation for the stock is said to be 2.20 (where 1=Buy, 5=sale).
Applied Micro Circuits Corporation (AMCC) offers connectivity and computing solutions in the United States and internationally. The company offers X-Gene, a server on a chip product for use in cloud data center, computing, and enterprise applications; and embedded computing products that are applied in control- and data-plane functionality, wireless access points, residential gateways, wireless base stations, storage controllers, network attached storage, network switches and routing products, and multi-function printers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
